Close

Antares Pharma Announces Next Generation of Auto-Injector Design

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares’ new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater in a compact design. VIBEX QS achieves this advance by incorporating a novel triggering mechanism and space-saving spring configuration. The new design also accommodates fast injection of highly-viscous drug products that stall less-powerful conventional auto-injectors.

VIBEX QS is designed to enhance the patient experience with self-administered parenteral drugs including most biological agents. Of the $50 billion U.S. market for biological drugs in 2009, we estimate that self-administered products accounted for over half the total. Biological drugs in particular face new competitive threats as biosimilar drugs are approved in Europe and the U.S. Our patented VIBEX delivery systems address self-injectable product manufacturers’ growing needs for product differentiation strategies especially as differences between the active ingredients of competing products become less apparent. Many self-injectable drugs currently marketed and in clinical development are formulated to be administered in a 1 mL dose volume, which the new VIBEX QS accommodates.

Latest stories

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back